S1PR4-dependent effects of Etrasimod on primary human myeloid immune cell activation
BackgroundSphingosine-1-phosphate (S1P) and its five receptors S1PR1-5 play an essential role in the migration, differentiation and activation of various immune cells. Several S1PR modulators with distinct selectivity have been recently approved for the treatment of various inflammatory diseases. Am...
Saved in:
| Main Authors: | Fiona K. Sailer, Megan A. Palmer, Blerina Aliraj, Jan Heering, Andreas Brockmann, Mohammed A. F. Elewa, Aissa Röhrig, Ewgenij Proschak, Dariusz T. Stepniak, Simeon Ramsey, Bernhard Brüne, Andreas Weigert |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1590816/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Unique pharmacological properties of etrasimod among S1P receptor modulators
by: Ibragim Gaidarov, et al.
Published: (2025-01-01) -
Safety, tolerability, pharmacokinetics, and pharmacodynamics of etrasimod in healthy Chinese adults: a randomized, double-blind, placebo-controlled dose-escalation phase 1 study
by: Fangfang Wang, et al.
Published: (2025-06-01) -
Model-Based Dose Selection of a Sphingosine-1-Phosphate Modulator, Etrasimod, in Patients with Various Degrees of Hepatic Impairment
by: Mohammed S. Alasmari, et al.
Published: (2024-12-01) -
Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis
by: Vipul Jairath, et al.
Published: (2025-02-01) -
Targeting sphingosine 1-phosphate and sphingosine kinases in pancreatic cancer: mechanisms and therapeutic potential
by: Khem Raj Limbu, et al.
Published: (2024-10-01)